Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving (177)Lu-PSMA-617 Radioligand Therapy

Rationale: PSMA-PET-CT enables measuring molecular expression of prostate-specific membrane antigen (PSMA) in vivo, which is the target molecule of (177)Lu-PSMA-617 (Lu-PSMA) therapy. However, the correlation of PSMA expression and overall survival (OS) in patients treated with Lu-PSMA therapy is cu...

Descripción completa

Detalles Bibliográficos
Autores principales: Seifert, Robert, Seitzer, Konstantin, Herrmann, Ken, Kessel, Katharina, Schäfers, Michael, Kleesiek, Jens, Weckesser, Matthias, Boegemann, Martin, Rahbar, Kambiz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359095/
https://www.ncbi.nlm.nih.gov/pubmed/32685021
http://dx.doi.org/10.7150/thno.47251

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359095/
https://www.ncbi.nlm.nih.gov/pubmed/32685021
http://dx.doi.org/10.7150/thno.47251

Ejemplares similares